title: Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009-2010 influenza vaccination in the Netherlands.
abstract: In the Netherlands, people indicated for seasonal influenza vaccination are divided in 3 risk groups, i.e. those less than 60 y (y) with comorbidity and those 60 y and over with and without comorbidity. Those risk groups were also eligible for pandemic vaccination during the 2009 influenza A(H1N1) pandemic. We assessed tolerability of seasonal influenza vaccination and 2 doses of pandemic influenza A(H1N1) vaccine, adjuvanted with MF-59, administered 2 and 5 weeks after seasonal 2009-2010 vaccination among adults. Vaccinees were asked to return questionnaires on local and systemic adverse events (AEs) after each of 3 consecutive vaccinations given at the office of their General Practitioner. Sex- and risk group-specific AE-frequencies were calculated. Generalized Linear Mixed Model with seasonal vaccination as reference was used to calculate odds ratios (ORs) for AEs of the 2 pandemic doses. 5553 questionnaires (3251 vaccinees) were returned. Vaccinees reported any local AE after seasonal vaccination and both pandemic doses in 34%, 23%, and 18%, respectively. These percentages were 29%, 25%, and 16% for any systemic AE. Men reported fewer local and systemic AEs then women (p<0.0001). The risk of local (OR range 0.34-0.63) and systemic (OR range 0.39-0.99) AEs (overall, stratified by risk group and by sex) was lower after both pandemic doses compared to seasonal vaccination. This decreased risk was more pronounced after the second pandemic dose than after the first. Therefore, we conclude that MF59-adjuvanted pandemic vaccine given after seasonal vaccination was well tolerated.
authors.affiliation: a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.
authors.forename: N A T
authors.initials: NA
authors.lastname: van der Maas
authors.affiliation: a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.|b Department of Health Science, VU University Amsterdam , Amsterdam , the Netherlands.
authors.forename: S
authors.initials: S
authors.lastname: Godefrooij
authors.affiliation: a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.
authors.forename: P E
authors.initials: PE
authors.lastname: Vermeer-de Bondt
authors.affiliation: a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.
authors.forename: H E
authors.initials: HE
authors.lastname: de Melker
authors.affiliation: a Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Kemmeren
mesh_terms: D000276:Adjuvants, Immunologic; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007115:Immunization Schedule; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D058873:Pandemics / Q000517:prevention & control*; D012621:Seasons; D011795:Surveys and Questionnaires; D014611:Vaccination; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; C558220:focetria
keywords: adverse event following immunization; influenza; pandemic; seasonal; tolerability; vaccination
references.citation: Int J Clin Pract. 2010 Mar;64(4):432-8
references.pmid: 20039974
references.citation: Vaccine. 1999 Jul 30;17 Suppl 1:S3-10
references.pmid: 10471173
references.citation: Curr Opin Immunol. 2009 Aug;21(4):418-24
references.pmid: 19570667
references.citation: Vaccine. 2009 Nov 16;27(49):6959-65
references.pmid: 19751689
references.citation: Int J Risk Saf Med. 2011;23(2):81-7
references.pmid: 21673415
references.citation: Vaccine. 2012 Jul 13;30(33):5030-7
references.pmid: 22472791
references.citation: Vaccine. 2014 Nov 20;32(49):6622-30
references.pmid: 25446824
references.citation: Vaccine. 2011 Feb 24;29(10):1941-7
references.pmid: 21236235
references.citation: Vaccine. 2009 Oct 23;27(45):6300-4
references.pmid: 19840664
references.citation: MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62
references.pmid: 20689501